Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIV - Takeaways - MDSpire

Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIV

  • By

  • Kara Wegermann

  • Ayako Suzuki

  • Elisa Sarmiento

  • LaKeisha Boyd

  • Yang Li

  • Laura A Wilson

  • Audrey Lloyd

  • Paula Debroy

  • Jennifer C Price

  • Tinsay Woreta

  • Holly Crandall

  • Richard K Sterling

  • Rohit Loomba

  • Naga Chalasani

  • Jordan E Lake

  • October 14, 2025

  • 0 min

Share

  • 1

    Men with HIV have a higher prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant fibrosis (CSF) than women.

  • 2

    Diabetes, hyperlipidemia, and high waist circumference are associated with increased odds of MASLD-CSF in men with HIV.

  • 3

    Female sex assigned at birth is protective against MASLD-CSF in individuals living with HIV.

  • 4

    The study highlights the need for targeted screening for MASLD in men with HIV, particularly those with specific comorbidities.

  • 5

    Further research is needed to explore the impact of menopause on MASLD prevalence and severity in women living with HIV.

Original Source(s)

Female Sex is Protective Against MASLD With Clinically Significant Fibrosis in a Large Cross-sectional Cohort of Persons With HIV

  • by Kara Wegermann, Ayako Suzuki, Elisa Sarmiento, LaKeisha Boyd, Yang Li, Laura A Wilson, Audrey Lloyd, Paula Debroy, Jennifer C Price, Tinsay Woreta, Holly Crandall, Richard K Sterling, Rohit Loomba, Naga Chalasani, Jordan E Lake

  • October 14, 2025

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Immunological research landscapes and emerging immune mechanisms in HIV/HBV co-infection: a bibliometric analysis (2014–2024)